Clinical, Histopathological and Therapeutic Characteristics of Thyroid Cancer in Colombia: A case series study including 1.096 patients
PDF (Español (España))
HTML (Español (España))


thyroid cancer

How to Cite

Wandurraga Sánchez, E. A., Marín Carrillo, L. F., Natera Melo, A. K., Giraldo, C. M. G., Niño Prato, F., Arenas Quintero, H. M., Bueno, R. C., López Pompey, N. A., De La Portilla Maya, D. A., Fériz Bonelo, K. M., Pinzón Tovar, A., Dueñas Muñoz, J. P., Abreu Lomba, A., Fierro Maya, L. F., Pinzón Barco, J. B., Torres Grajales, J. L., Palacio Barrientos, A. F., Sánchez Orduz, L., & García Rey, R. E. (2019). Clinical, Histopathological and Therapeutic Characteristics of Thyroid Cancer in Colombia: A case series study including 1.096 patients. Revista Endocrino, 6(1), 5–12.


Background: Cancer registries are useful to determine the magnitude of the problem, but not enough to provide meaningful variables for clinicians or to serve as a source of hypotheses for research. Our objective was to identify the clinical characteristics of thyroid cancer patients, initial therapeutic approach and costs associated with the management of the disease.

Methods: A descriptive, observational case series study with thyroid cancer patients was conducted (2013 - 2015) in 10 cities in Colombia. A web-based tool ( was developed to include patient data (55 variables, including demographic, histopathological, paraclinical and therapeutic characteristics).

Results: Information of 1,096 patients with thyroid cancer was included (Mean age: 45.5 years; 86.3% women). 93.6% of cases were papillary carcinoma. Association between tumour size and capsular, extracapsular, lymphovascular, central and lateral lymph node involvement was documented (p=0.000). Patients under 45 years showed greater central (p=0.000) and lateral (p=0.003) lymph node invasion while in patients over 45, multifocal tumours (p=0.032) and extracapsular infiltration (p=0.036) were more frequent. The approximate direct cost/patient/year was COP$2,532,687 (USD 982).

Conclusions: This registry shows that papillary thyroid carcinoma accounts for 93.6% of all types of thyroid cancer, a higher percentage than reported in other series in the literature; 89% of patients were classified as high and intermediate risk of recurrence following initial cancer therapy. In patients under 45 years, the disease tends to disseminate via the lymphatic system, but in patients over 45 local extensions are more frequent. Finally, approximate disease cost was estimated at USD 982/patient/year.
PDF (Español (España))
HTML (Español (España))


1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009 Nov;19(11):1167-214.
2. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. World Health Organization.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
4. Gagel RF, Goepfert H, Callender DL. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46: 261-283.
5. Garavito G, Llamas Olier A, Cadena E, De Los Reyes A, Hurtado G, Rojas L, et al. Manejo multidisciplinario del cáncer diferenciado de tiroides en el Instituto Nacional de Cancerología. Rev Colomb Cancerol. 2010; 14(2):65-77.
6. Cendales R, Pardo C, Uribe C, López G, Yepes MC, Bravo LE. Calidad de los datos en los registro de cáncer de base de población en Colombia. Biomédica. 2012; 32(4):536-44.
8. Xu S, Chen G, Peng W, Renko K, Derwahl M. Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules? J Endocrinol. 2013 Jun 1;218(1):125-33.
9. M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL. Unbalanced estrogen metabolism in thyroid cancer. Int J Cancer. 2013 Dec 1;133(11):2642-9.
10. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010 Jan;20(1):33-41.
11. Veiga LH, Neta G, Aschebroo Kilfoy B, Ron E, Devesa SS. Thyroid cancer incidence patterns in Sao Paulo, Brazil and the US SEER program 1997-2008. Thyroid. 2013; 23(6:748-57).
12. Cuellar AA, Franco R, Valero MV. Desórdenes por deficiencia de yodo: Bocio endémico. Correlación entre la presencia de bocio y factores de crecimiento. Universidad Nacional de Colombia, Facultad de Medicina, Trabajo de grado. 2010.
13. Petterson B, Adami ho, Wilander E, Coleman MP. Trends in thyroid cáncer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer. 1991; 48 (1):28.
14. Hay ID, Hutchinson ME, Gonzalez-Losada T, Mclver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144(6):980-7.
15. Ito Y1, Masuoka H, Fukushima M. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg. 2010 Jun;34(6):1285-90.
16. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and folicullar thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-63.
17. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cáncer. Thyroid. 2016 See comment in PubMed Commons below Jan;26(1):1-133.
18. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009 Oct;53(7):884-7.
19. Acuerdo No. 256 DE 2.001. Por el cual se aprueba el “Manual de Tarifas” de la Entidad Promotora de Salud del Seguro Social “EPS-ISS”. https://lexsaludcolombia.files.wordpress/2010/10/tarifas-iss-2001.pdf

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here


Download data is not yet available.